Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebamipide for Prevention of Naproxen-Induced Gastric Lesions
NCT02632812Phase 1Completed
- Sponsor
- Biolab Farmacêutica
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in gastrointestinal lesion comparing Rebamipide & Naproxen with Placebo & Naproxen (2 arms). Primary endpoints: Endoscopic Score - Cryer Score at 8 days, Endoscopic Score - Modified Lanza Score at 8 days and 4 more. Started Oct 2014; status: completed.
02
Drugs
rebamipide
03
Conditions
gastrointestinal lesion
Beyond the preview
Go deeper on NCT02632812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632812.